GlassScriptPhysician profile
Rodrine Asante Buffaloe
NPI 1700171584
$4,640.35
in general payments reported to CMS, 2019-2025
27 companies · $559 in 2025
The $559 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $507 · 2021: $1,117 · 2022: $706 · 2023: $554 · 2024: $589 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,702 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.65 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $584.25 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $554.45 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $483.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $431.99 | 2019-2023 | Steglatro |
| Glaxosmithkline, LLC. | $321.03 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $309.00 | 2021-2025 | Ubrelvy |
| Astellas Pharma US INC | $270.58 | 2019-2025 | Veozah |
| Pfizer INC. | $221.80 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.26 | 2020-2025 | Synjardy, Tradjenta, Jardiance |
| Abbott Laboratories | $200.08 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $149.77 | 2020-2025 | Repatha, Otezla, Otezla |
| Dexcom, INC. | $134.96 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $134.47 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $133.69 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $79.61 | 2023-2025 | Gemtesa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $65.60 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Topcon Healthcare, INC. | $60.24 | 2019 | |
| Esperion Therapeutics, INC. | $47.40 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $47.29 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Allergan, INC. | $39.79 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.49 | 2022 | |
| Phathom Pharmaceuticals, INC. | $30.74 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $28.83 | 2024-2025 | |
| Ultragenyx Pharmaceutical INC. | $23.60 | 2022 | |
| Scilex Pharmaceuticals INC. | $18.27 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.18 | 2021 | |
| Amarin Pharma, INC. | $14.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodrine Buffaloe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.